2026-06-15 Otsuka Holdings Co.,Ltd. “Regarding the completion of the acquisition of Transcend Therapeutics.”
2026-06-15 Otsuka Holdings Co.,Ltd. “Regarding the completion of the acquisition of Transcend Therapeuti … 続きを読む
JP3188220002
2026-06-11 Otsuka Holdings Co.,Ltd. “58 years after its launch, Bon Curry's familiar taste is being passed on to the next generation. Otsuka Foods' Lake Biwa Research Institute has developed a taste and recipe prediction AI system called "Oishisa LENS" and has begun using it for technology transfer and product design.”
2026-06-11 Otsuka Holdings Co.,Ltd. “58 years after its launch, Bon Curry's familiar taste is being … 続きを読む
2026-06-10 Otsuka Holdings Co.,Ltd. “Otsuka Chemical and Gutenberg are collaborating with three student groups participating in the NHK Student Robot Contest using 3D printing technology.”
2026-06-10 Otsuka Holdings Co.,Ltd. “Otsuka Chemical and Gutenberg are collaborating with three student … 続きを読む
2026-06-05 Otsuka Holdings Co.,Ltd. “VOYXACT (sibeprenelimab), a treatment for IgA nephropathy, presents favorable eGFR data from a Phase 3 trial – reporting 12 months of maintained renal function at the European Society of Nephrology.”
2026-06-05 Otsuka Holdings Co.,Ltd. “VOYXACT (sibeprenelimab), a treatment for IgA nephropathy, presents … 続きを読む
2026-06-05 Otsuka Holdings Co.,Ltd. “The National Institute for Environmental Studies and other organizations have established the "Heatstroke Prevention Industry-Government-Academia Collaboration Consortium" to bring together scientific and practical knowledge to reduce the risk of heatstroke caused by climate change.”
2026-06-05 Otsuka Holdings Co.,Ltd. “The National Institute for Environmental Studies and other organiza … 続きを読む
2026-05-29 Otsuka Holdings Co.,Ltd. “Centanafazine, a novel attention-deficit/hyperactivity disorder (ADHD) treatment with a new mechanism of action, was presented at the American Society of Clinical Psychopharmacology (ASCP) annual meeting with post-hoc analysis results from a Phase 3 trial demonstrating improvements in executive function and emotional regulation in adults with ADHD.”
2026-05-29 Otsuka Holdings Co.,Ltd. “Centanafazine, a novel attention-deficit/hyperactivity disorder (AD … 続きを読む
2026-05-18 Otsuka Holdings Co.,Ltd. “FACEDUO launches new program "Heatstroke Prevention VR" to allow users to experience the signs of heatstroke and take action to prevent it from occurring or becoming severe in the elderly.”
2026-05-18 Otsuka Holdings Co.,Ltd. “FACEDUO launches new program "Heatstroke Prevention VR" t … 続きを読む
2026-05-14 Otsuka Holdings Co.,Ltd. “The US FDA has approved INQOVI and venetoclax combination therapy as the first oral-only combination therapy for patients with acute myeloid leukemia who are not suitable for intensive induction therapy.”
2026-05-14 Otsuka Holdings Co.,Ltd. “The US FDA has approved INQOVI and venetoclax combination therapy a … 続きを読む
2026-04-30 Otsuka Holdings Co.,Ltd. “Otsuka Pharmaceutical has released a collection of educational materials and resources for teachers and staff to support health education in schools. Electronic health materials on topics such as heatstroke prevention and nutrition education are available free of charge.”
2026-04-30 Otsuka Holdings Co.,Ltd. “Otsuka Pharmaceutical has released a collection of educational mate … 続きを読む
2026-04-28 Otsuka Holdings Co.,Ltd. “Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics have had their New Drug Application (NDA) for diparereltinib for locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations accepted by the U.S. FDA.”
2026-04-28 Otsuka Holdings Co.,Ltd. “Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics hav … 続きを読む